 InPharm | Novo Nordisk and Merrion Sign €1.5M Deal for Oral Formulation Technology Genetic Engineering News Following the completion of feasibility studies Novo Nordisk will have an option to license the GIPET technology. The firms already have existing license ... Novo Nordisk buys rights to Emisphere technology for oral insulin for $57.5 ... |
Source: news.google.com
No comments:
Post a Comment